Skip to main content
Tourmaline Bio, Inc. logo

Tourmaline Bio, Inc. — Investor Relations & Filings

Ticker · TRML ISIN · US87410C1045 US Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2024-04-19 Proxy Solicitation & In…
Country US United States of America
Listing US TRML

About Tourmaline Bio, Inc.

https://www.tourmalinebio.com/

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company focused on developing transformative medicines for patients with life-altering inflammatory and immune diseases. The company's lead asset is pacibekitug, a monoclonal antibody that targets the interleukin-6 (IL-6) cytokine, a key driver of inflammation. Pacibekitug is being developed as a potential treatment for a range of conditions, with a primary focus on atherosclerotic cardiovascular disease (ASCVD) and other severe autoimmune and inflammatory disorders, aiming to establish a new standard of care in areas with high unmet medical need.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2024-04-19 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Tourmaline Bio, Inc. It registers additional shares under the company's 2023 Equity Incentive Plan and 2023 Employee Stock Purchase Plan. The document includes legal and procedural information related to the registration of securities for employee benefit plans. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2024-03-19 English
10-K
Annual Report FY 2023
2024-03-19 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release with financial results for the quarter and year ended December 31, 2023. However, the document itself does not contain detailed financial statements or substantive financial data; it only furnishes a press release as an exhibit. The document length is 4006 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a current report announcing financial results but does not contain the full financial report itself. It is not an Earnings Release (ER) because it is a formal SEC filing (8-K) referencing a press release, and the press release is attached as an exhibit rather than included in full text here. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-03-19 English
SC 13G/A
Major Shareholding Notification
2024-02-15 English
SC 13G
Major Shareholding Notification
2024-02-15 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.